Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 3 8Phase 1/2 7Phase 1 4

Status

Completed 3Unknown 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4

Interventions

pembrolizumab 93Nivolumab 61Docetaxel 55Cyclophosphamide 49enzalutamide 44Magnetic Resonance Spectroscopy 33Ipilimumab 33Gemcitabine 32Abiraterone Acetate 30Prednisone 29fludarabine 28Everolimus 27Paclitaxel 25Cisplatin 24Radiotherapy 23Carboplatin 23Sunitinib 22cabozantinib 21atezolizumab 20Radiosurgery 20Specimen Handling 19Sorafenib 18Bevacizumab 18pazopanib 17bicalutamide 17abiraterone 17Biopsy 15temsirolimus 14darolutamide 14apalutamide 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Estramustine × Genitourinary × Clear all
NCT00002721 2014-05-21

Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

University of New Mexico

Phase 1 Completed
18 enrolled
Genitourinary

Prostatic Neoplasms

NCT00003633 2013-12-19

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

National Cancer Institute (NCI)

Phase 1 Unknown
12 enrolled
Genitourinary

Prostatic Neoplasms

NCT00005627 2013-07-18

Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

National Cancer Institute (NCI)

Phase 1 Completed
Genitourinary

Prostatic Neoplasms

NCT00005048 2012-11-09

Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

NYU Langone Health

Phase 1 Completed
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡